Ex vivo expanded autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cell therapy (University of Alberta)

N/A

Report date: 2022/12/25 13:45:36

Base Information

Drug NameEx vivo expanded autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cell therapy (University of Alberta)
Drug Alias NamePolyTregsPolyclonal Regulatory T Cell (PolyTreg) Immunotherapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alberta
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Alberta
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A